GLP Watchdog

Does Medicare Pay for GLP-1 Medications? (2026)

Medicare covers GLP-1 medications only in limited cases; prior authorization is required, and members who are approved typically pay $30-$100 a month.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

Where Medicare stands[1]
Limited
67,000,000 members · Prior authorization needed
Limited

Where Each Medication Stands[4]

MedicationWhat Medicare does
Wegovy (semaglutide)Medicare Part D excludes drugs prescribed for weight loss under the statutory exclusion at SSA 1860D-2(e)(2)(A). The exception is written into the diagnosis, not the drug: per the CMS HPMS memo issued March 20, 2024, Part D can pay for Wegovy where the prescription carries the FDA-approved cardiovascular-risk-reduction indication - reducing risk of MACE in adults with established CVD who are obese or overweight, on the strength of the SELECT trial. Plan-level coverage and PA criteria vary.
Ozempic (semaglutide)Covered under Medicare Part D for type 2 diabetes diagnosis.
Zepbound (tirzepatide)Not covered under Medicare Part D for weight loss (statutory exclusion). Sleep apnea is the exception worth knowing about: Zepbound holds its own FDA approval in adults who have obesity together with moderate-to-severe obstructive sleep apnea, and whether Part D pays on that indication comes down to the individual plan.
Mounjaro (tirzepatide)Covered under Medicare Part D for type 2 diabetes diagnosis.
Copay when it is covered$30-$100 / month

What a GLP-1 costs a Medicare member

At Medicare's typical copay of $30-$100 a month, a covered year of a GLP-1 costs $360 to $1,200. That is $2,988 to $3,828 less than a year of Wegovy bought for cash from NovoCare ($4,188), and Zepbound's LillyDirect price of $299 to $449 a month is further above it still.

The cheapest compounded option, Collective at $59/mo ($708 a year), lands inside the Medicare range, and 48 sellers charge no more than the $100 top of it, so for a member facing that copay a denial costs less than it sounds.

Medicare is a government plan, and every manufacturer savings card for Wegovy, Ozempic, Zepbound and Mounjaro excludes government-plan members. Novo Nordisk's Wegovy terms say the exclusion holds even if you pay cash and never bill the plan, so the cash comparison for a Medicare member is the manufacturer's self-pay price or a compounded seller.

The Medicare GLP-1 Bridge and the Part D cap

Part D cannot pay for a drug used for weight loss alone, but the Medicare GLP-1 Bridge lets eligible Part D members get Zepbound KwikPen or Foundayo for weight management for no more than $50 a month, with prior authorization and a BMI of 35, or 27 with certain conditions. Where Part D does pay for a GLP-1, such as Ozempic or Mounjaro for type 2 diabetes, your yearly out-of-pocket spending on covered drugs stops at $2,100 in 2026.

After a Denial from Medicare

A Medicare denial leaves two routes: an appeal, and paying cash. With a prescription, a brand-name GLP-1 is generally an eligible HSA or FSA medical expense[2]. Compounded semaglutide and tirzepatide from licensed 503A pharmacies[3] cost far less than the brand; the cheapest sellers are listed below.

Why Medicare is different: statute settles this one, not plan policy. Part D cannot pay for what the law calls “agents when used for anorexia, weight loss, or weight gain”, a bar written into the Social Security Act at § 1860D-2(e)(2)(A). So an obesity indication gets nowhere with Wegovy or Zepbound, even on a plan whose formulary already lists them for diabetes or cardiovascular use[1].

Where to go if Medicare says no

Sellers that say they work with Medicare

Sellers that mention Medicare
#SellerCash priceVisit
1Shapely$99/moVisit
2Klinic$299/moVisit
3Enara HealthPrice not publishedVisit

The 8 cheapest cash-pay compounded GLP-1s

Cheapest cash-pay compounded GLP-1 sellers
#SellerMonthly priceVisit
1Collective
Compounded semaglutide
$59/moVisit
2Boston Medical Group
Compounded semaglutide
$66/moVisit
3OurView Health
Compounded semaglutide
$75/moVisit
4Ivim Health
Compounded semaglutide
$75/moVisit
5Embody
Compounded semaglutide
$79/moVisit
6Lean Meds
Compounded semaglutide
$79/moVisit
7NextMeds
Compounded semaglutide
$79/moVisit
8NuuVim
Compounded semaglutide
$79/moVisit

Every seller and price, side by side: compare all sellers.

Our picks

#ProviderScore
1Trimi HealthVisit
2EmbodyVisit
3CoreAge RxVisit
4bmiMDVisit
5Live VitalVisit

Frequently Asked Questions

Medicare Part D excludes drugs prescribed for weight loss under the statutory exclusion at SSA 1860D-2(e)(2)(A). The exception is written into the diagnosis, not the drug: per the CMS HPMS memo issued March 20, 2024, Part D can pay for Wegovy where the prescription carries the FDA-approved cardiovascular-risk-reduction indication - reducing risk of MACE in adults with established CVD who are obese or overweight, on the strength of the SELECT trial. Plan-level coverage and PA criteria vary.
Covered under Medicare Part D for type 2 diabetes diagnosis.
Not covered under Medicare Part D for weight loss (statutory exclusion). Sleep apnea is the exception worth knowing about: Zepbound holds its own FDA approval in adults who have obesity together with moderate-to-severe obstructive sleep apnea, and whether Part D pays on that indication comes down to the individual plan.
Covered under Medicare Part D for type 2 diabetes diagnosis.
Members who are approved typically pay $30-$100 a month, which is $360 to $1,200 over a year. As a Medicare member you cannot use a manufacturer savings card.
Appeal first: ask Medicare for the written denial and the criteria it applied, and have your prescriber answer them in a letter of medical necessity. If the appeal fails, the cheapest cash route is compounded semaglutide or tirzepatide, from Collective at $59/mo or Boston Medical Group at $66/mo. Sellers that say they work with Medicare include Shapely, Klinic and Enara Health. A compounded drug is not FDA-approved as a finished product.

Glossary

The words sellers use, defined. Tap any term.

How coverage looks nationallyWork out the cash-pay difference
Sources & methodology — as of September 2026
  1. 1.CMS — Medicare Part D Prescription Drug Coverage Program— Centers for Medicare & Medicaid Services.
  2. 2.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.
  3. 3.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  4. 4.GLP Watchdog insurer coverage index (manually curated formulary data)— GLP Watchdog.